The first big decision after a multiple sclerosis diagnosis is not whether to treat. It is which medication to choose, and then how to tell whether it is doing its job when you cannot feel it working. The choice comes down to how active your MS is, which risks you can accept, and which schedule you will keep. A medication is working when you have no new relapses, no new lesions on MRI, and a stable examination.
There are more than 20 approved disease-modifying therapies, with different strengths, risks, and schedules. Most people leave their first neurology appointment with a list of names and no way to compare them. This guide gives you the framework a neurologist uses to narrow that list, tables that match the options to common situations and compare the MS pills side by side, and the specific things that show a treatment is working. The detailed topics, such as comparing the B-cell therapies, reading your MRI, the neurofilament blood test, and what to do in a relapse, each have their own article.
What MS medications do
MS is an autoimmune condition in which the immune system attacks myelin, the insulating coating around nerve fibers in the brain and spinal cord. The main medications are called disease-modifying therapies (DMTs). They work on the immune system to reduce the frequency and severity of relapses, prevent or slow the formation of new lesions, and delay the build-up of disability.
Two things about DMTs surprise people. First, they cannot reverse damage that has already happened, so the best time to start is early, before damage accumulates. Second, you do not feel them working. A pain reliever gives immediate relief; a DMT prevents attacks that would otherwise have happened. That is why objective monitoring, described below, matters so much.
How to choose an MS medication: three questions
Every treatment decision comes down to weighing three things. Your neurologist brings the medical evidence to each; you bring what matters in your life.
1. How active is your MS?
Frequent relapses, many lesions on MRI, lesions in the spinal cord or brainstem, incomplete recovery from an attack, and early disability all point to more active disease, which justifies a more effective medication from the start. DMTs are often grouped by efficacy: older injectables are moderately effective, most oral medications are in the middle, and the monoclonal antibody infusions and injections are the most effective at preventing relapses and new lesions.
There have been two schools of thought. One starts with a moderate medication and steps up if the disease breaks through. The other starts with a highly effective therapy straight away. Comparative studies increasingly favor starting strong, especially when MS is active, because MS tends to be most inflammatory in its early years and that is when protection matters most. As people get older and inflammatory activity naturally settles, it is often possible to move to a medication with simpler monitoring. Your neurologist will tell you where your MS sits on this spectrum.
2. What risks and monitoring can you accept?
More effective medications generally carry more risk or need closer monitoring. Older injectables have decades of safety data and few serious risks. Higher-efficacy therapies may require screening blood tests before starting, regular blood work during treatment, infusion monitoring, or surveillance for specific complications. Your other health conditions, your history of infections, and your own comfort with risk all feed into this.
3. What will you actually keep up?
The most effective medication in a trial is worthless if it is missed. Daily pills, self-injections, and infusions at a center every six months each suit different lives. Travel, work schedules, needle comfort, distance from an infusion center, and plans for pregnancy are legitimate medical considerations, not afterthoughts. People who choose a treatment that fits their routine are more likely to stay on it, and staying on it is what protects the brain.
Visual guide
Three questions guide treatment choice
- Disease activity: Review relapses and MRI findings with your neurologist.
- Risks and monitoring: Discuss side effects, other health conditions, and required checks.
- A workable schedule: Choose a treatment routine you can reliably maintain.
Which option fits which situation
The three questions play out differently in common situations. This table shows the usual starting points, not rules: every row is a conversation with your neurologist.
| Situation | Usually considered | Usually avoided | Why |
|---|---|---|---|
| Planning a pregnancy soon | Glatiramer acetate or interferon beta, which can be continued until pregnancy is confirmed; or an anti-CD20 therapy with the last dose timed before conception | Teriflunomide and cladribine, and an S1P modulator without a planned switch | Some medicines can harm a developing baby or linger in the body, and stopping an S1P modulator abruptly can bring rebound activity |
| Dislikes needles | Pills, or an infusion every six months | Frequent self-injections | A treatment you will keep taking protects more than one you dread |
| Travels often | Pills, a monthly self-injection pen, or an infusion twice a year | Infusions every four weeks | Fewer fixed appointments; pills and pens travel, though pens may need refrigeration |
| Highly active MS or spinal cord lesions | A high-efficacy therapy from the start: an anti-CD20 therapy or natalizumab, and sometimes cladribine | Starting low and waiting to step up | Early, strong control matters most when MS is active, and spinal cord lesions carry more risk of lasting disability |
| JC virus antibody positive | An anti-CD20 therapy or another high-efficacy option | Long-term natalizumab, especially with a high antibody level | The JC virus can cause PML, a rare brain infection, in people on natalizumab |
| Liver disease | Glatiramer acetate, or an anti-CD20 therapy after hepatitis B screening | Teriflunomide; interferons need closer liver monitoring | Teriflunomide and interferons can injure the liver, and anti-CD20 therapies can reactivate hepatitis B |
| Over 55 and stable for years | Continuing a well-tolerated medicine, or stepping down to one with simpler monitoring | Escalating without new activity, or stopping treatment altogether | Inflammatory activity tends to settle with age while infection risk rises, so the balance of benefit and risk shifts |
How MS treatment schedules compare
This table groups the approved therapies by how they are taken. It is meant for comparison, not as a recommendation for any individual.
| Category | Examples | Schedule | What to know |
|---|---|---|---|
| Injectable, older | Interferon beta-1a, interferon beta-1b and peginterferon beta-1a; glatiramer acetate | Self-injection, from daily to every two weeks depending on the product | Moderate efficacy, long safety record, few serious risks. Flu-like symptoms with interferons; injection-site reactions with both. Often chosen when safety or pregnancy planning is the priority |
| Oral, S1P modulators | Fingolimod, siponimod, ozanimod, ponesimod | One pill daily | Good to high efficacy. Keep immune cells in the lymph nodes. Heart rhythm monitoring at the start for some, periodic eye and blood checks. Stopping suddenly can cause rebound activity, so changes are planned |
| Oral, fumarates | Dimethyl fumarate, diroximel fumarate, monomethyl fumarate | Twice daily | Good efficacy. Flushing and stomach upset early on that usually settle; blood counts monitored |
| Oral, other | Teriflunomide; cladribine | Teriflunomide daily; cladribine in two short courses a year apart, then no further treatment in years three and four | Teriflunomide needs liver monitoring and careful pregnancy planning. Cladribine works by resetting part of the immune system; blood counts are monitored |
| Anti-CD20 B-cell therapies | Ocrelizumab (an IV infusion, or an injection given by a clinician), ofatumumab (a self-injection), ublituximab (an infusion) | Ocrelizumab and ublituximab every six months; ofatumumab monthly at home | High efficacy. Screening for hepatitis B and vaccine review before starting; infusion or injection reactions; increased infection risk; immunoglobulin levels tracked over time. Ocrelizumab is also approved for primary progressive MS |
| Infusion, other | Natalizumab; alemtuzumab | Natalizumab every four weeks; alemtuzumab in two courses a year apart | Natalizumab has very high efficacy and requires ongoing JC virus antibody testing because of the risk of a rare brain infection (PML). Alemtuzumab has very high, long-lasting efficacy and is reserved for active disease because of a substantial risk of new autoimmune conditions, with monthly blood monitoring for years afterward |
MS pills compared
If you would rather not inject or sit through infusions, there are four groups of MS pills. They differ in how often you take them, how strongly they control MS, and what they ask of you in monitoring and family planning.
| Pill | How often | Efficacy | Main monitoring | Pregnancy note |
|---|---|---|---|---|
| Fumarates (dimethyl fumarate, diroximel fumarate, monomethyl fumarate) | Twice a day | Good | Blood counts, especially lymphocytes, and liver tests | They clear the body quickly, so they are usually stopped shortly before trying to conceive |
| S1P modulators (fingolimod, siponimod, ozanimod, ponesimod) | Once a day | Good to high | A heart rhythm check at the start for some, eye and blood checks, and chickenpox immunity before starting | Stopped well before conception, with a planned switch, because stopping can bring rebound activity |
| Teriflunomide | Once a day | Moderate | Liver tests, blood counts and blood pressure | Must be avoided in pregnancy; it lingers in the body, so a specific elimination procedure comes first |
| Cladribine | Two short courses of tablets a year apart, then no treatment in years three and four | High | Lymphocyte counts before and after each course | Pregnancy is avoided during the treatment years and for a period after each course |
How side effects and risks affect the choice
Side effects are one of the strongest influences on which medication is right for you, and they deserve an honest conversation rather than a scan of a package insert.
- Nuisance side effects are common, usually temporary, and rarely dangerous: flu-like symptoms with interferons, flushing and stomach upset with fumarates, injection-site reactions, hair thinning with teriflunomide, mild reactions during infusions. They matter because they affect whether you will keep taking the medication.
- Infection risk rises with most higher-efficacy therapies. For most people this means more colds and urinary infections rather than serious illness, and vaccinations are reviewed before starting.
- Rare serious risks are specific to particular drugs: PML with natalizumab, secondary autoimmunity with alemtuzumab, cardiac effects at the start of S1P modulators, liver injury with teriflunomide. Each has a monitoring plan designed to catch problems early, and each is a reason a given drug may be the wrong choice for a given person.
- Your own history changes the calculation. Prior serious infections, liver or heart disease, a positive JC virus test, or plans to become pregnant can rule a medication in or out before anything else is considered.
Not everyone gets side effects, and a long list of possible effects is not a list of guaranteed ones. The goal is a medication whose risks you understand and accept, with monitoring that makes those risks manageable.
What to ask before starting an MS medication
Come to the decision visit with questions written down. These are the ones that produce the most useful answers.
- Why this medication for my MS specifically, rather than the alternatives?
- How effective is it compared with the other options you considered?
- What side effects are common, and which serious risks does it carry?
- What monitoring will I need, how often, and what happens if a test is abnormal?
- How does it fit with my plans for work, travel, or a family?
- What would tell us it is not working, and what would we switch to?
- How long before it takes full effect?
How I choose a medication with patients
Here is how I approach it at our MS clinic. Before we talk about any drug, I look at your actual MRI images, not only the report, and at your history: how many relapses, how well you recovered, and where the lesions sit. That answers the first of the three questions, how active your MS is.
Then I ask about your life. Are you planning a pregnancy in the next few years? How do you feel about needles? How often do you travel, and how far is the nearest infusion center? What other health conditions and medicines do you have? Those answers usually narrow the list to two or three options.
When the MS is active, or there are lesions in the spinal cord or brainstem, I generally recommend starting with a highly effective therapy rather than working up to one. When it is mild and something else is the priority, such as a pregnancy soon, a moderate-efficacy option can be the right start, with a clear plan for what would make us change.
We go through the shortlist together: how each medicine is taken, what the monitoring involves, and the common side effects and the rare serious ones. I tell you what I would recommend and why, and the decision is yours. Before you start, we arrange the screening blood work and vaccine review, and we handle the prior authorization.
Then we measure. I record your walking, hand function and thinking at the start, repeat the timed walk and peg test at follow-up visits, and compare follow-up MRIs with a new baseline, so we can tell early whether the choice is working.
How to know your MS medication is working
Once you have started, the question becomes whether it is helping. Because DMTs work silently, the answer comes from four kinds of evidence, and a good follow-up plan tracks all of them.
1. No relapses, or far fewer
The most direct measure. If you had two relapses in the year before starting and none in the year after, the treatment is doing its job. A relapse in the first few months does not necessarily mean failure, because most DMTs take several months to reach full effect. Our guide to MS relapses explains how to tell a true relapse from a temporary flare caused by heat, infection, or exhaustion.
2. No new lesions on MRI
MRI is the most objective monitoring tool. After a new treatment starts, a baseline scan is usually obtained, and follow-up scans are then compared against it for new or enlarging lesions, contrast-enhancing lesions, and brain volume change. How often you are scanned depends on how active your MS has been and how long you have been stable; your neurologist sets that schedule. A stable MRI is good news even when old lesions are still visible. It means no new lesions have appeared. Our guide to understanding your MS brain MRI covers what the report means.
3. A stable examination
Your neurologist tracks walking, balance, coordination, vision, strength, sensation, and thinking at each visit, sometimes with standardized scales such as the EDSS. The aim is to prevent new disability from accumulating. Function that was affected before treatment may or may not improve; what matters is that nothing new is lost.
4. Neurofilament light chain, where available
Neurofilament light chain (NfL) is a protein released into the blood when nerve fibers are injured. Measured before a treatment starts and again some months later, a fall into the range expected for your age supports that the medication is controlling inflammation, and a persistently high or rising level can flag activity between MRI scans. It is interpreted alongside the scan and the examination, never on its own.
Neurologists call the target no evidence of disease activity, or NEDA. The formal definition, NEDA-3, is three things: no relapses, no new MRI activity, and no confirmed disability progression. The third has to be measured on function, because progression can accumulate without relapses or new lesions. A stricter version, NEDA-4, adds a normal rate of brain volume loss. Neurofilament light chain is not part of either definition, but it is increasingly tracked alongside them. In MS, the absence of disease activity is success, even if you still carry symptoms from before treatment began.
Visual guide
Check whether treatment is controlling MS
- Relapses: Report new neurological episodes or clearly worsening symptoms.
- MRI: Follow-up scans look for new disease activity.
- Examination: Stable neurological function is another part of the assessment.
When a treatment is not working
Patience in the early months is reasonable. Beyond that, a change should be considered if you have relapses after the medication has had time to take effect, if follow-up MRI shows new or enlarging lesions, if your examination is worsening without obvious relapses, if NfL stays elevated despite treatment, or if side effects are damaging your quality of life. A relapse on treatment is information, not failure: it means this medication is not the right fit, and there are many alternatives.
Never stop or change a DMT on your own. Some medications cause a rebound of disease activity when stopped abruptly, occasionally worse than the original MS. Any change should be planned with your neurologist, who will time the transition and arrange monitoring around it.
Reasons people switch
- Breakthrough disease activity, usually prompting a move to a more effective therapy
- Side effects that do not settle
- Life changes, such as planning a pregnancy, a new job, or frequent travel
- New options that did not exist when you started
- Simplification later in life, when inflammatory activity has quieted and a medication with less monitoring may be appropriate
Even when everything is going well, treatment is reviewed periodically: are the goals being met, has the disease changed, has your life changed, is there a better option now than there was then.
Beyond the medication
A DMT is the foundation of MS treatment, not the whole of it. Regular exercise, sleep, vascular health, stress management, and adequate vitamin D all support brain health and are covered in our guide to lifestyle changes for brain health in MS. Acute relapses are treated separately with short courses of corticosteroids. Symptoms such as spasticity, bladder problems, pain, fatigue, and brain fog have their own treatments, and physical, occupational, and cognitive rehabilitation each have a place. Depression and anxiety are common in MS, treatable, and worth raising with your neurologist, because they make everything else harder.
What new treatments are coming?
Research is moving quickly. BTK inhibitors, a new class of oral medication that acts on immune cells inside the nervous system as well as in the blood, are the closest to the clinic. In September 2026 the FDA accepted an application for one of them, fenebrutinib, for priority review in relapsing and primary progressive MS. None is approved yet. Liver safety is the main open question: in December 2025 the FDA declined to approve another, tolebrutinib, citing liver injury and unclear benefit. Remyelination and neuroprotection strategies aim to repair or shield nerve fibers rather than only preventing new attacks. Blood biomarkers are becoming more precise. For people with highly active MS that has not responded to standard treatment, stem cell transplantation is being studied at specialized centers. If you are interested in participating, our clinical trials page explains how that works.
Talking it through with an MS specialist
Choosing a DMT is a shared decision. Your neurologist knows the medications and your disease; you know your life. The best outcomes come when both are in the room. Leaving an appointment with a list of drug names and no way to compare them is overwhelming. At a multiple sclerosis evaluation, the 60-minute first visit with Dr. Achillefs Ntranos is spent reviewing your history and actual MRI images, narrowing that list to options that fit your MS and your life, and setting up the monitoring that will show whether the choice is working. Follow-ups are usually every one to three months and last 30 to 45 minutes, and messages between visits are answered within 1 business day. Request a visit in Beverly Hills or Los Angeles, or by video anywhere in California. No referral is needed, and the office confirms within 1 business day.
Frequently asked questions
References
- National Multiple Sclerosis Society. Disease-modifying therapies for MS.
- Rae-Grant A, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology, 2018.
- Choosing initial MS therapy: personal, disease, and medication factors. 2025.
- MS Trust. Disease modifying therapies.
- National Institute of Neurological Disorders and Stroke. Multiple sclerosis.
- MS Trust. NEDA (no evidence of disease activity).
- Pandit L. No evidence of disease activity (NEDA) in multiple sclerosis: shifting the goal posts. Frontiers in Neurology, 2019.
- EMD Serono. MAVENCLAD (cladribine) prescribing information. DailyMed, US National Library of Medicine.
- Teva Neuroscience. COPAXONE (glatiramer acetate) prescribing information. DailyMed, US National Library of Medicine.
- Cleveland Clinic. Sphingosine-1-phosphate receptor modulators in multiple sclerosis.
- Roche. Fenebrutinib receives U.S. FDA filing acceptance under priority review in relapsing and primary progressive multiple sclerosis. Media release, September 30, 2026.
- Sanofi. FDA complete response letter for tolebrutinib in non-relapsing secondary progressive multiple sclerosis. Press release, December 24, 2025.
- Corboy JR, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS). Lancet Neurology, 2023.